Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

ClinicalTrials.gov ID: NCT03152552

Public ClinicalTrials.gov record NCT03152552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure

Study identification

NCT ID
NCT03152552
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
125 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 24, 2017
Primary completion
Jun 5, 2018
Completion
Jun 5, 2018
Last update posted
Aug 27, 2019

2017 – 2018

United States locations

U.S. sites
21
U.S. states
12
U.S. cities
21
Facility City State ZIP Site status
Novartis Investigative Site Huntsville Alabama 35801
Novartis Investigative Site Carmichael California 95608
Novartis Investigative Site Concord California 94520
Novartis Investigative Site Long Beach California 90813
Novartis Investigative Site Northridge California 91325
Novartis Investigative Site Stockton California 95204
Novartis Investigative Site Colorado Springs Colorado 80906
Novartis Investigative Site Bradenton Florida 34209
Novartis Investigative Site Clearwater Florida 33756
Novartis Investigative Site Delray Beach Florida 33446
Novartis Investigative Site Fort Lauderdale Florida 33312
Novartis Investigative Site Gurnee Illinois 60031
Novartis Investigative Site Bogalusa Louisiana 70427
Novartis Investigative Site Jackson Mississippi 39209
Novartis Investigative Site St Louis Missouri 63128
Novartis Investigative Site Omaha Nebraska 68114
Novartis Investigative Site Charleston South Carolina 29407
Novartis Investigative Site Columbia South Carolina 29203
Novartis Investigative Site San Antonio Texas 78229
Novartis Investigative Site Sugar Land Texas 77479
Novartis Investigative Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03152552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 27, 2019 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03152552 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →